The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented...
Read More Details
Finally We wish PressBee provided you with enough information of ( Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance )
Also on site :
- China says U.S. dialogue to continue as China hints trade talks are advancing
- SUNMI Opens Its First North American Store in Atlanta
- Fire Breaks Out at a Data Center Leased by Elon Musk’s X